Chennai-based direct-to-patient platform MrMed is strengthening its nationwide presence through new on-ground operations in Guwahati and a dedicated cold-chain facility in Bengaluru, while venturing into allied super-specialty healthcare services like home-based cancer care to enhance patient convenience and treatment continuity.
Glimpse:
MrMed has expanded operations to Guwahati, launched an offline cold-chain storage hub in Bengaluru, and outlined plans for further city-level infrastructure growth across India. The moves focus on faster last-mile delivery of critical, temperature-sensitive super-specialty medicines. Simultaneously, the company is entering allied services, starting with home-based cancer care offerings such as nurse-led infusions and pre- and post-chemotherapy support. This evolution builds on MrMed’s core strength in sourcing and delivering life-saving therapies from major pharma partners, aiming to reduce hospital visits, improve access in underserved regions, and position the platform as a more comprehensive healthcare enabler for patients with chronic and critical conditions.
MrMed, a Chennai-headquartered direct-to-patient platform specializing in critical care and super-specialty medicines, has announced a strategic expansion phase to bolster its physical footprint and broaden its role in India’s healthcare ecosystem. The company, which partners with authorized distributors of leading Indian and global pharmaceutical firms including Eli Lilly, Novo Nordisk, Cipla, Dr Reddy’s, and Mankind has long focused on ensuring timely access to approved, high-cost therapies across the country.
Recent developments include the opening of on-ground operations in Guwahati, expanding its presence beyond Chennai, Delhi, and Bengaluru. This addition targets improved last-mile access in the Northeast, where logistics for temperature-sensitive and life-saving drugs can be particularly challenging. Complementing this is the launch of a dedicated offline cold-chain storage facility in Bengaluru, designed to accelerate fulfilment times and enhance reliability for patients in Karnataka and across South India. Chennai continues to serve as the central operations and pharmacy hub, while MrMed advances plans to establish physical infrastructure in additional cities nationwide.
Beyond logistics, MrMed is stepping into allied super-specialty healthcare services to support patients more holistically. The initial focus is on home-based cancer care, introducing nurse-led infusions along with pre- and post-chemotherapy support. These services aim to minimize repeated hospital visits for patients on prolonged treatment cycles, reduce the burden on families, and promote better continuity of care—particularly valuable for oncology patients requiring consistent monitoring and administration.
The expansion reflects MrMed’s response to key pain points in specialty medicine delivery: delays in fulfilment, cold-chain integrity risks, and the inconvenience of frequent hospital trips for supportive care. By combining robust distribution with select direct-care offerings, the platform seeks to deliver greater convenience, affordability, and outcomes for patients facing critical illnesses.
This growth phase positions MrMed as an evolving player in India’s digital health landscape, bridging online pharmacy strengths with on-ground service delivery to address gaps in access for super-specialty treatments.
“Expanding into allied super-specialty services allows us to support patients through nurse-led infusions and pre- and post-chemotherapy care, reducing repeated hospital visits and ensuring continuity of care for those on long-term treatment cycles.”
By
HB Team
